Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

Author： Venturini M.   Bighin C.   Monfardini S.   Cappuzzo F.   Olmeo N.   Durando A.   Puglisi F.   Nicoletto O.   Lambiase A.   Mastro L.  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.95, Iss.1, 2006-01, pp. : 45-53

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase II Trial of Vinflunine As Monotherapy or in Combination with Trastuzumab as First-Line Treatment of Metastatic Breast Cancer

By Yardley Denise A.   McCleod Michael   Schreiber Fred   Murphy Patrick   Patton Jeffrey   Thompson Dana S.   Shastry Mythili   Rubin Mark   Melnik Marianne   Burris Howard A.   Hainsworth John D.  

Cancer Investigation, Vol. 28, Iss. 9, 2010-10 ,pp. : 925-931

Informa Healthcare

Access to resources Recommend Favorite

A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study)

By Aogi Kenjiro   Saeki Toshiaki   Nakamura Seigo   Kashiwaba Masahiro   Sato Nobuaki   Masuda Norikazu   Rai Yoshiaki   Ohno Shinji   Kuroi Katsumasa   Nishimura Reiki   Miyakoda Keiko   Akiyama Futoshi   Kurosumi Masafumi   Ikeda Tadashi  

International Journal of Clinical Oncology, Vol. 18, Iss. 4, 2013-08 ,pp. : 598-606

Springer Publishing Company

Access to resources Recommend Favorite

Docetaxel and Epirubicin as First-Line Treatment for Patients with Metastatic Breast Cancer: A Minnie Pearl Cancer Research Network Phase II Trial

By Hainsworth John   Yardley Denise   Spigel David   Meluch Anthony   Rinaldi David   Schnell Frederick   Greco F.  

Cancer Investigation, Vol. 24, Iss. 5, 2006-06 ,pp. : 469-473

Informa Healthcare

Access to resources Recommend Favorite

A Phase II Multicenter Study of Two Different Dosages of Pemetrexed Given in Combination With Cyclophosphamide as First-Line Treatment in Patients With Locally Advanced or Metastatic Breast Cancer

By Dittrich Christian   Solska Ewa   Manikhas Alexey   Eniu Alexandru   Tjulandin Sergei   Anghel Rodica   Musib Luna   Frimodt-Moller Bente   Liu Yushan   Krejcy Kurt   Láng István  

Cancer Investigation, Vol. 30, Iss. 4, 2012-04 ,pp. : 309-316

Informa Healthcare

Access to resources Recommend Favorite

Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study

By Morales Serafín   Lorenzo Antonio   Ramos Manuel   Ballesteros Pedro   Méndez Miguel   Almanza Concepción   Castellanos Javier   Moreno-Nogueira José   Casal Joaquín   Lizón José   Oltra Amparo   Frau Adolfo   Machengs Ignacio   Galán Antonio   Belón Joaquín   Llorca Cristina  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 1, 2004-01 ,pp. : 75-81

Springer Publishing Company

Access to resources Recommend Favorite